MTARC1 and metabolic dysfunction-associated steatotic liver disease: There are in vivo studies on mice with a liver-specific siRNA-mediated Mtarc1 knockdown, which have been conducted by pharmaceutical companies seeking to use this strategy as a therapeutical intervention for treatment of NAFLD.